{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:26:27Z","timestamp":1790519187564,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>New molecular mechanisms that can be targeted with specific drugs have recently emerged for the treatment of systemic sclerosis (SSc) patients. Over the past 3 years, the achievement of one large phase 3 trial has led to the approval by drug agencies of the first drug licenced for SSc-related interstitial lung disease. Given this exciting time in the SSc field, we aimed to perform a systemic literature review of phase 1, phase 2 and phase 3 clinical trials and large observational studies about targeted therapies in SSc. We searched MEDLINE\/PubMed, EMBASE, and <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> for clinical studies from 2016 with targeted therapies as the primary treatment in patients with SSc for skin or lung involvement as the primary clinical outcome measure. Details on the study characteristics, the trial drug used, the molecular target engaged by the trial drug, the inclusion criteria of the study, the treatment dose, the possibility of concomitant immunosuppression, the endpoints of the study, the duration of the study and the results obtained were reviewed. Of the 973 references identified, 21 (4 conference abstracts and 17 articles) were included in the systematic review. A total of 15 phase 1\/phase 2 clinical trials, 2 phase 3 clinical trials and 2 observation studies were analysed. The drugs studied in phase 1\/phase 2 studies included the following: inebilizumab, dabigatran, C-82, pomalidomide, rilonacept, romilkimab, tocilizumab, tofacitinib, pirfenidone, lenabasum, abatacept, belimumab, riociguat, SAR100842 and lanifibranor. All but 3 studies were performed in early diffuse SSc patients with different inclusion criteria, while 3 studies were performed in SSc patients with interstitial lung disease (ILD). Phase 3 clinical trials investigated nintedanib and tocilizumab. Nintedanib was investigated in SSc-ILD patients whereas tocilizumab focused on early diffuse SSc patients with inflammatory features. Two observational studies including &gt;\u200950 patients with rituximab as the targeted drug were also evaluated. All these studies offer a real hope for SSc patients. The future challenges will be to customize patient-specific therapeutics with the goal to develop precision medicine for SSc.<\/jats:p>","DOI":"10.1186\/s13075-021-02536-5","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T13:21:20Z","timestamp":1622553680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3\u2009years"],"prefix":"10.1186","volume":"23","author":[{"given":"Corrado","family":"Campochiaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"issue":"10103","key":"2536_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685\u201399. https:\/\/doi.org\/10.1016\/S0140-6736(17)30933-9.","journal-title":"Lancet"},{"issue":"1","key":"2536_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.semarthrit.2018.11.002","volume":"49","author":"LA Garc\u00eda Rodr\u00edguez","year":"2019","unstructured":"Garc\u00eda Rodr\u00edguez LA, Gonz\u00e1lez-P\u00e9rez A, Michel A, S\u00e1ez ME. Contemporary epidemiology of systemic sclerosis: a population-based cohort study in the United Kingdom. Semin Arthritis Rheum. 2019;49(1):105\u201311. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.11.002.","journal-title":"Semin Arthritis Rheum"},{"key":"2536_CR3","doi-asserted-by":"publisher","unstructured":"Allanore Y, Simms R, Distler O, Trojanowska M, Pope J, Denton CP, et al. Systemic sclerosis. Nat Rev Dis Prim. 2015;1(1). https:\/\/doi.org\/10.1038\/nrdp.2015.2.","DOI":"10.1038\/nrdp.2015.2"},{"issue":"4","key":"2536_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41584-019-0184-z","volume":"15","author":"ER Volkmann","year":"2019","unstructured":"Volkmann ER, Varga J. Emerging targets of disease-modifying therapy for systemic sclerosis. Nat Rev Rheumatol. 2019;15(4):208\u201324. https:\/\/doi.org\/10.1038\/s41584-019-0184-z.","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"2536_CR5","doi-asserted-by":"publisher","first-page":"6635","DOI":"10.4049\/jimmunol.165.11.6635","volume":"165","author":"S Sato","year":"2000","unstructured":"Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol. 2000;165(11):6635\u201343. https:\/\/doi.org\/10.4049\/jimmunol.165.11.6635.","journal-title":"J Immunol"},{"issue":"4","key":"2536_CR6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1365-2141.2011.08857.x","volume":"155","author":"E Ward","year":"2011","unstructured":"Ward E, Mittereder N, Kuta E, Sims GP, Bowen MA, Dall\u2019Acqua W, et al. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol. 2011;155(4):426\u201337. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08857.x.","journal-title":"Br J Haematol"},{"issue":"1","key":"2536_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/S13075-016-1021-2","volume":"18","author":"E Schiopu","year":"2016","unstructured":"Schiopu E, Chatterjee S, Hsu V, Flor A, Cimbora D, Patra K, et al. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther. 2016;18(1):131. https:\/\/doi.org\/10.1186\/S13075-016-1021-2.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"2536_CR8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.semarthrit.2010.10.002","volume":"41","author":"A Ludwicka-Bradley","year":"2011","unstructured":"Ludwicka-Bradley A, Silver RM, Bogatkevich GS. Coagulation and autoimmunity in scleroderma interstitial lung disease. Semin Arthritis Rheum. 2011;41(2):212\u201322. https:\/\/doi.org\/10.1016\/j.semarthrit.2010.10.002.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"2536_CR9","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1002\/art.30255","volume":"63","author":"GS Bogatkevich","year":"2011","unstructured":"Bogatkevich GS, Ludwicka-Bradley A, Nietert PJ, Akter T, van Ryn J, Silver RM. Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease. Arthritis Rheum. 2011;63(5):1416\u201325. https:\/\/doi.org\/10.1002\/art.30255.","journal-title":"Arthritis Rheum"},{"key":"2536_CR10","unstructured":"Lumpkin TB, et al. Direct thrombin inhibition with dabigatran alters the matrix-induced, pro-fibrotic phenotype of fibroblasts. Am J Respir Crit Care Med. 2018."},{"issue":"7","key":"2536_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/acr2.11049","volume":"1","author":"RM Silver","year":"2019","unstructured":"Silver RM, Wilson DA, Akter T, Atanelishvili I, Huggins JT, Kajdasz K, et al. Safety and tolerability of thrombin inhibition in scleroderma-associated interstitial lung disease. ACR Open Rheumatol. 2019;1(7):403\u201311. https:\/\/doi.org\/10.1002\/acr2.11049.","journal-title":"ACR Open Rheumatol"},{"issue":"10","key":"2536_CR12","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1096\/fj.201600502R","volume":"30","author":"D Bastakoty","year":"2016","unstructured":"Bastakoty D, Young PP. Wnt\/\u03b2-catenin pathway in tissue injury: roles in pathology and therapeutic opportunities for regeneration. FASEB J. 2016;30(10):3271\u201384. https:\/\/doi.org\/10.1096\/fj.201600502R.","journal-title":"FASEB J"},{"issue":"8","key":"2536_CR13","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/emboj\/19.8.1839","volume":"19","author":"A Hecht","year":"2000","unstructured":"Hecht A. The p300\/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. EMBO J. 2000;19(8):1839\u201350. https:\/\/doi.org\/10.1093\/emboj\/19.8.1839.","journal-title":"EMBO J"},{"issue":"12","key":"2536_CR14","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1016\/j.jid.2017.06.032","volume":"137","author":"R Lafyatis","year":"2017","unstructured":"Lafyatis R, Mantero JC, Gordon J, Kishore N, Carns M, Dittrich H, et al. Inhibition of \u03b2-catenin signaling in the skin rescues cutaneous adipogenesis in systemic sclerosis: a randomized, double-blind, placebo-controlled trial of C-82. J Invest Dermatol. 2017;137(12):2473\u201383. https:\/\/doi.org\/10.1016\/j.jid.2017.06.032.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"2536_CR15","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1136\/annrheumdis-2012-201784","volume":"71","author":"S Weing\u00e4rtner","year":"2012","unstructured":"Weing\u00e4rtner S, Zerr P, Tomcik M, Palumbo-Zerr K, Distler A, Dees C, et al. Pomalidomideis effective for prevention and treatment of experimental skin fibrosis. Ann Rheum Dis. 2012;71(11):1895\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201784.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2536_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1006\/clim.2000.4920","volume":"97","author":"SJ Oliver","year":"2000","unstructured":"Oliver SJ, Moreira A, Kaplan G. Immune stimulation in scleroderma patients treated with thalidomide. Clin Immunol. 2000;97(2):109\u201320. https:\/\/doi.org\/10.1006\/clim.2000.4920.","journal-title":"Clin Immunol"},{"issue":"3","key":"2536_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3899\/jrheum.161040","volume":"45","author":"VM Hsu","year":"2018","unstructured":"Hsu VM, Denton CP, Domsic RT, Furst DE, Rischmueller M, Stanislav M, et al. Pomalidomide in patients with interstitial lung disease due to systemic sclerosis: A phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. J Rheumatol. 2018;45(3):405\u201310. https:\/\/doi.org\/10.3899\/jrheum.161040.","journal-title":"J Rheumatol"},{"issue":"6","key":"2536_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1358\/dot.2009.45.6.1378935","volume":"45","author":"MF McDermott","year":"2009","unstructured":"McDermott MF. Rilonacept in the treatment of chronic inflammatory disorders. Drugs Today. 2009;45(6):423\u201330. https:\/\/doi.org\/10.1358\/dot.2009.45.6.1378935.","journal-title":"Drugs Today"},{"issue":"8","key":"2536_CR19","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.4049\/jimmunol.175.8.5390","volume":"175","author":"P Bonniaud","year":"2005","unstructured":"Bonniaud P, Margetts PJ, Ask K, Flanders K, Gauldie J, Kolb M. TGF-\u03b2 and Smad3 signaling link inflammation to chronic fibrogenesis. J Immunol. 2005;175(8):5390\u20135. https:\/\/doi.org\/10.4049\/jimmunol.175.8.5390.","journal-title":"J Immunol"},{"key":"2536_CR20","unstructured":"Mantero JC, et al. Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I\/II biomarker trial. Clin Exp Rheumatol. 2018."},{"issue":"2","key":"2536_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40259-019-00400-2","volume":"34","author":"Q Zhao","year":"2020","unstructured":"Zhao Q. Bispecific antibodies for autoimmune and inflammatory diseases: clinical progress to date. BioDrugs. 2020;34(2):111\u20139. https:\/\/doi.org\/10.1007\/s40259-019-00400-2.","journal-title":"BioDrugs"},{"issue":"3","key":"2536_CR22","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.cyto.2011.08.030","volume":"56","author":"P Fuschiotti","year":"2011","unstructured":"Fuschiotti P. Role of IL-13 in systemic sclerosis. Cytokine. 2011;56(3):544\u20139. https:\/\/doi.org\/10.1016\/j.cyto.2011.08.030.","journal-title":"Cytokine"},{"key":"2536_CR23","doi-asserted-by":"crossref","unstructured":"Allanore Y, Denton C, Khanna D, et al. Efficacy and safety of romilkimab in diffuse cutaneous systemic sclerosis (dcSSc): a randomized, double-blind, placebo-controlled, 24-week, proof of concept study [abstract]. Arthritis Rheum. 2019;71(suppl 10).","DOI":"10.1136\/annrheumdis-2020-eular.4830"},{"issue":"4","key":"2536_CR24","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1038\/cti.2013.2","volume":"2","author":"S O\u2019Reilly","year":"2013","unstructured":"O\u2019Reilly S, Cant R, Ciechomska M, et al. Interleukin-6: a new therapeutic target in systemic sclerosis? Clin Transl Immunol. 2013;2(4):e4. https:\/\/doi.org\/10.1038\/cti.2013.2.","journal-title":"Clin Transl Immunol"},{"issue":"4","key":"2536_CR25","doi-asserted-by":"publisher","first-page":"R157","DOI":"10.1186\/ar4672","volume":"16","author":"L Desallais","year":"2014","unstructured":"Desallais L, Avouac J, Frechet M, et al. Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. Arthritis Res Ther. 2014;16(4):R157. https:\/\/doi.org\/10.1186\/ar4672.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"2536_CR26","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1136\/annrheumdis-2011-200955","volume":"71","author":"K Khan","year":"2012","unstructured":"Khan K, Xu S, Nihtyanova S, Derrett-Smith E, Abraham D, Denton CP, et al. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis. 2012;71(7):1235\u201342. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200955.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2536_CR27","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3899\/jrheum.120725","volume":"40","author":"A De Lauretis","year":"2013","unstructured":"De Lauretis A, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol. 2013;40(4):435\u201346. https:\/\/doi.org\/10.3899\/jrheum.120725.","journal-title":"J Rheumatol"},{"issue":"10038","key":"2536_CR28","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038):2630\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(16)00232-4.","journal-title":"Lancet"},{"issue":"9","key":"2536_CR29","doi-asserted-by":"publisher","first-page":"5903","DOI":"10.1002\/jcp.29593","volume":"235","author":"A Hosseini","year":"2020","unstructured":"Hosseini A, Gharibi T, Marofi F, Javadian M, Babaloo Z, Baradaran B. Janus kinase inhibitors: a therapeutic strategy for cancer and autoimmune diseases. J Cell Physiol. 2020;235(9):5903\u201324. https:\/\/doi.org\/10.1002\/jcp.29593.","journal-title":"J Cell Physiol"},{"key":"2536_CR30","doi-asserted-by":"crossref","unstructured":"Wang W, Bhattacharyya S, Goncalves Marangoni R, et al. The JAK\/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib, August 2019. J Scleroderma Relat Dis. 5(2):239719831986536.","DOI":"10.1177\/2397198319865367"},{"key":"2536_CR31","doi-asserted-by":"publisher","unstructured":"Goll GL, Kvien TK. New-generation JAK inhibitors: how selective can they be? Lancet. 2018. https:\/\/doi.org\/10.1016\/S0140-6736(18)31325-4.","DOI":"10.1016\/S0140-6736(18)31325-4"},{"key":"2536_CR32","first-page":"114103","volume":"178","author":"A Lescoat","year":"2020","unstructured":"Lescoat A, Lelong M, Jelijeli M, et al. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: perspectives for scleroderma-associated interstitial lung disease. BiochemPharmacol. 2020;178:114103.","journal-title":"BiochemPharmacol."},{"key":"2536_CR33","unstructured":"Khanna D, Bush E, Nagaraja V, et al. Tofacitinib in early diffuse cutaneous systemic sclerosis\u2014results of phase I\/II investigator-initiated, double-blind randomized placebo-controlled trial [abstract]. Arthritis Rheum. 2019;71(suppl 10)."},{"issue":"9779","key":"2536_CR34","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet. 2011;377(9779):1760\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(11)60405-4.","journal-title":"Lancet"},{"issue":"2","key":"2536_CR35","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/1756-185X.13247","volume":"21","author":"H Xiao","year":"2018","unstructured":"Xiao H, Zhang GF, Liao XP, Li XJ, Zhang J, Lin H, et al. Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease. Int J Rheum Dis. 2018;21(2):477\u201386. https:\/\/doi.org\/10.1111\/1756-185X.13247.","journal-title":"Int J Rheum Dis"},{"issue":"9","key":"2536_CR36","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3899\/jrheum.151322","volume":"43","author":"D Khanna","year":"2016","unstructured":"Khanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung L, et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: The LOTUSS trial. J Rheumatol. 2016;43(9):1672\u20139. https:\/\/doi.org\/10.3899\/jrheum.151322.","journal-title":"J Rheumatol"},{"issue":"9","key":"2536_CR37","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1136\/annrheumdis-2011-200314","volume":"71","author":"EG Gonzalez","year":"2012","unstructured":"Gonzalez EG, Selvi E, Balistreri E, Akhmetshina A, Palumbo K, Lorenzini S, et al. Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis. Ann Rheum Dis. 2012;71(9):1545\u201351. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200314.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2536_CR38","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1096\/fj.201600646R","volume":"30","author":"RB Zurier","year":"2016","unstructured":"Zurier RB, Burstein SH. Cannabinoids, inflammation, and fibrosis. FASEB J. 2016;30(11):3682\u20139. https:\/\/doi.org\/10.1096\/fj.201600646R.","journal-title":"FASEB J"},{"issue":"8","key":"2536_CR39","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1002\/art.41294","volume":"72","author":"R Spiera","year":"2020","unstructured":"Spiera R, Hummers L, Chung L, Frech TM, Domsic R, Hsu V, et al. Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with systemic sclerosis. Arthritis Rheum. 2020;72(8):1350\u201360. https:\/\/doi.org\/10.1002\/art.41294.","journal-title":"Arthritis Rheum"},{"key":"2536_CR40","doi-asserted-by":"crossref","unstructured":"Spiera R, Hummers L, Chung L, et al. Safety and efficacy of lenabasum at 21\u2009months in an open-label extension of a phase 2 study in diffuse cutaneous systemic sclerosis subjects [abstract]. Arthritis Rheum. 2019;71(suppl 10).","DOI":"10.1136\/annrheumdis-2019-eular.3390"},{"issue":"1","key":"2536_CR41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13075-018-1694-9","volume":"20","author":"G Boleto","year":"2018","unstructured":"Boleto G, Guignabert C, Pezet S, Cauvet A, Sadoine J, Tu L, et al. T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis. Arthritis Res Ther. 2018;20(1):197. https:\/\/doi.org\/10.1186\/s13075-018-1694-9.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2536_CR42","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/art.41055","volume":"72","author":"D Khanna","year":"2020","unstructured":"Khanna D, Spino C, Johnson S, Chung L, Whitfield ML, Denton CP, et al. Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2020;72(1):125\u201336. https:\/\/doi.org\/10.1002\/art.41055.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"2536_CR43","doi-asserted-by":"publisher","first-page":"e743","DOI":"10.1016\/S2665-9913(20)30237-X","volume":"2","author":"L Chung","year":"2020","unstructured":"Chung L, Spino C, McLain R, Johnson SR, Denton CP, Molitor JA, et al. Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. Lancet Rheumatol. 2020;2(12):e743\u201353. https:\/\/doi.org\/10.1016\/S2665-9913(20)30237-X.","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"2536_CR44","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/art.20274","volume":"50","author":"S Sato","year":"2004","unstructured":"Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: Expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum. 2004;50(6):1918\u201327. https:\/\/doi.org\/10.1002\/art.20274.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2536_CR45","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.clinthera.2012.02.028","volume":"34","author":"EG Boyce","year":"2012","unstructured":"Boyce EG, Fusco BE. Belimumab: review of use in systemic lupus erythematosus. Clin Ther. 2012;34(5):1006\u201322. https:\/\/doi.org\/10.1016\/j.clinthera.2012.02.028.","journal-title":"Clin Ther"},{"issue":"2","key":"2536_CR46","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/art.40358","volume":"70","author":"JK Gordon","year":"2018","unstructured":"Gordon JK, Martyanov V, Franks JM, Bernstein EJ, Szymonifka J, Magro C, et al. Belimumab for the treatment of early diffuse systemic sclerosis. Arthritis Rheum. 2018;70(2):308\u201316. https:\/\/doi.org\/10.1002\/art.40358.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2536_CR47","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1209655","volume":"369","author":"HA Ghofrani","year":"2013","unstructured":"Ghofrani HA, Gali\u00e8 N, Grimminger F, Gr\u00fcnig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1209655.","journal-title":"N Engl J Med"},{"issue":"5","key":"2536_CR48","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","volume":"79","author":"D Khanna","year":"2020","unstructured":"Khanna D, Allanore Y, Denton CP, Kuwana M, Matucci-Cerinic M, Pope JE, et al. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Ann Rheum Dis. 2020;79(5):618\u201325. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216823.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2536_CR49","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bbalip.2012.06.014","volume":"1831","author":"Y Zhao","year":"2013","unstructured":"Zhao Y, Natarajan V. Lysophosphatidic acid (LPA) and its receptors: role in airway inflammation and remodeling. Biochim Biophys Acta Mol Cell Biol Lipids. 2013;1831(1):86\u201392. https:\/\/doi.org\/10.1016\/j.bbalip.2012.06.014.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"10","key":"2536_CR50","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/art.40547","volume":"70","author":"Y Allanore","year":"2018","unstructured":"Allanore Y, Distler O, Jagerschmidt A, Illiano S, Ledein L, Boitier E, et al. Lysophosphatidic acid receptor 1 antagonist SAR100842 for patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2018;70(10):1634\u201343. https:\/\/doi.org\/10.1002\/art.40547.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"2536_CR51","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1136\/annrheumdis-2015-208029","volume":"75","author":"N Ruzehaji","year":"2016","unstructured":"Ruzehaji N, Frantz C, Ponsoye M, Avouac J, Pezet S, Guilbert T, et al. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. Ann Rheum Dis. 2016;75(12):2175\u201383. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208029.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2536_CR52","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1183\/09031936.00174914","volume":"45","author":"L Wollin","year":"2015","unstructured":"Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1434\u201345. https:\/\/doi.org\/10.1183\/09031936.00174914.","journal-title":"Eur Respir J"},{"issue":"5","key":"2536_CR53","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/annrheumdis-2014-207109","volume":"75","author":"J Huang","year":"2016","unstructured":"Huang J, Beyer C, Palumbo-Zerr K, Zhang Y, Ramming A, Distler A, et al. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis. 2016;75(5):883\u201390. https:\/\/doi.org\/10.1136\/annrheumdis-2014-207109.","journal-title":"Ann Rheum Dis"},{"issue":"22","key":"2536_CR54","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382. https:\/\/doi.org\/10.1056\/NEJMoa1402584.","journal-title":"N Engl J Med"},{"issue":"26","key":"2536_CR55","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1903076.","journal-title":"N Engl J Med"},{"key":"2536_CR56","unstructured":"Khanna D, Lin CJF, Kuwana M, et al. Efficacy and safety of tocilizumab for the treatment of systemic sclerosis: results from a phase 3 randomized controlled trial [abstract]. Arthritis Rheum. 2018;70(suppl 10)."},{"issue":"7","key":"2536_CR57","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","volume":"78","author":"M Elhai","year":"2019","unstructured":"Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, et al. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: A prospective cohort study. Ann Rheum Dis. 2019;78(7):979\u201387. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214816.","journal-title":"Ann Rheum Dis"},{"key":"2536_CR58","doi-asserted-by":"publisher","unstructured":"Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: Open label, randomized, controlled trial. Rheumatol. 2018. https:\/\/doi.org\/10.1093\/rheumatology\/key213.","DOI":"10.1093\/rheumatology\/key213"},{"key":"2536_CR59","doi-asserted-by":"publisher","unstructured":"Brown M, O\u2019Reilly S. The immunopathogenesis of fibrosis in systemic sclerosis. Clin Exp Immunol. 2019. https:\/\/doi.org\/10.1111\/cei.13238.","DOI":"10.1111\/cei.13238"},{"issue":"3","key":"2536_CR60","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.semarthrit.2019.09.019","volume":"49","author":"CP Denton","year":"2019","unstructured":"Denton CP. Challenges in systemic sclerosis trial design. Semin Arthritis Rheum. 2019;49(3):S3\u20137. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.09.019.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"2536_CR61","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1016\/S2665-9913(20)30007-2","volume":"2","author":"F Del Galdo","year":"2020","unstructured":"Del Galdo F, Hartley C, Allanore Y. Randomised controlled trials in systemic sclerosis: patient selection and endpoints for next generation trials. Lancet Rheumatol. 2020;2(3):e173\u201384. https:\/\/doi.org\/10.1016\/S2665-9913(20)30007-2.","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"2536_CR62","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327\u201339. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209909.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2536_CR63","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.semarthrit.2019.06.012","volume":"50","author":"FA Mendoza","year":"2020","unstructured":"Mendoza FA, Lee-Ching C, Jimenez SA. Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis. Semin Arthritis Rheum. 2020;50(1):135\u20139. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.06.012.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"2536_CR64","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1136\/annrheumdis-2016-210236","volume":"76","author":"JG Coghlan","year":"2017","unstructured":"Coghlan JG, Gali\u00e8 N, Barber\u00e0 JA, Frost AE, Ghofrani HA, Hoeper MM, et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis. 2017;76(7):1219\u201327. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210236.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2536_CR65","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","volume":"9","author":"KB Highland","year":"2021","unstructured":"Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, et al. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med. 2021;9(1):96\u2013106. https:\/\/doi.org\/10.1016\/S2213-2600(20)30330-1.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"2536_CR66","doi-asserted-by":"publisher","first-page":"101469","DOI":"10.1016\/j.berh.2019.101469","volume":"34","author":"A Quinlivan","year":"2020","unstructured":"Quinlivan A, Ross L, Proudman S, et al. Systemic sclerosis: advances towards stratified medicine. Best Pract Res Clin Rheumatol. 2020;34(1):101469. https:\/\/doi.org\/10.1016\/j.berh.2019.101469.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"2536_CR67","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s13063-017-2016-2","volume":"18","author":"P Saunders","year":"2017","unstructured":"Saunders P, Tsipouri V, Keir G, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomized controlled trial. Trials. 2017;18(1):275. https:\/\/doi.org\/10.1186\/s13063-017-2016-2.","journal-title":"Trials"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02536-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-021-02536-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02536-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T13:24:28Z","timestamp":1622553868000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02536-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2536"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02536-5","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]},"assertion":[{"value":"9 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CC declares no conflict of interests relevant to the content of this article. YA reports personal fees from Actelion, Bayer, BMS, Boehringer and Curzion, and grants and personal fees from Inventiva, Roche and Sanofi.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}